[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:nectin-4":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Nectin-4",5,3,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06311214","Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.118704Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06265727","A Phase 1\u002F2 Study to Investigate CRB-701 in Solid Tumors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:21.385056Z","2026-05-05T02:43:26.692408Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07139977","Study of EV for Recurrent Endometrial Carcinoma",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.320525Z",{"nct_id":30,"title":31,"phases":32,"status":33,"updated_at":34,"content_modified":35},"NCT07667335","Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer",[20],"NOT_YET_RECRUITING","2026-08-26T02:15:11.740957Z","2026-07-05T03:45:20.368868Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT06781983","Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors",[40],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:47:53.324478Z","2026-05-05T02:43:27.424580Z"]